Trials / Completed

CompletedNCT00329173

PULSAR - A Prospective Study to Evaluate the Utility of Low Doses of the Statins Atorvastatin and Rosuvastatin.

A 6-Week Open-Label, Randomised, Multicentre, Phase IIIb, Parallel-Group Study to Compare the Efficacy and Safety of Rosuvastatin (10 mg) With Atorvastatin (20 mg) in Subjects With Hypercholesterolaemia and Either a History of CHD or Clinical Evidence of CHD

Status: Completed
Phase: Phase 3
Study type: Interventional
Enrollment: 1,000 (planned)

Sponsor: AstraZeneca · Industry
Sex: All
Age: 18 Years
Healthy volunteers: Not accepted

Summary

To compare reduction of LDL-C and safety between 10mg rosuvastatin and 20mg atorvastatin after 6 weeks treatment

Conditions

Hypercholesterolaemia

Interventions

Type	Name	Description
DRUG	Rosuvastatin
DRUG	Atorvastatin

Timeline

Start date: 2003-11-01
Completion: 2004-08-01
First posted: 2006-05-24
Last updated: 2009-03-16

Source: ClinicalTrials.gov record NCT00329173. Inclusion in this directory is not an endorsement.